BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23294041)

  • 1. Azacitidine-eligibility in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukaemia: a registry-based study.
    Durairaj S; Keenan N; Hyslop A; Groves MJ; Bowen DT; Tauro S
    Br J Haematol; 2013 Apr; 161(2):280-2. PubMed ID: 23294041
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.
    Voso MT; Breccia M; Lunghi M; Poloni A; Niscola P; Finelli C; Bari A; Musto P; Zambello R; Fianchi L; Alimena G; Leone G
    Eur J Haematol; 2013 Apr; 90(4):345-8. PubMed ID: 23336938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
    Itzykson R; Thépot S; Beyne-Rauzy O; Ame S; Isnard F; Dreyfus F; Salanoubat C; Taksin AL; Chelgoum Y; Berthon C; Malfuson JV; Legros L; Vey N; Turlure P; Gardin C; Boehrer S; Ades L; Fenaux P;
    Leuk Res; 2012 Apr; 36(4):397-400. PubMed ID: 22177456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Fraison JB; Mekinian A; Grignano E; Kahn JE; Arlet JB; Decaux O; Denis G; Buchdahl AL; Omouri M; Maigne G; Aouba A; Leon N; Berthier S; Liozon E; Park S; Gardin C; Lortholary O; Rossignol J; Fenaux P; Fain O; Braun T
    Leuk Res; 2016 Apr; 43():13-7. PubMed ID: 26922775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
    García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
    Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
    Garcia-Manero G; Gore SD; Cogle C; Ward R; Shi T; Macbeth KJ; Laille E; Giordano H; Sakoian S; Jabbour E; Kantarjian H; Skikne B
    J Clin Oncol; 2011 Jun; 29(18):2521-7. PubMed ID: 21576646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.
    Kenealy M; Hertzberg M; Benson W; Taylor K; Cunningham I; Stevenson W; Hiwase D; Eek R; Zantomio D; Jong S; Wall M; Blombery P; Gerber T; Debrincat M; Zannino D; Seymour JF
    Haematologica; 2019 Apr; 104(4):700-709. PubMed ID: 30545923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
    van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
    Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose decitabine and high-risk MDS.
    Raza A; Raza FZ; Galili N
    Blood; 2006 Dec; 108(13):4291; author reply 4291-2. PubMed ID: 17148594
    [No Abstract]   [Full Text] [Related]  

  • 10. Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score.
    Falantes J; Delgado RG; Calderón-Cabrera C; Márquez-Malaver FJ; Valcarcel D; de Miguel D; Bailén A; Bargay J; Bernal T; González-Porras JR; Tormo M; Ramos F; Andreu R; Xicoy B; Nomdedeu B; Brunet S; Sánchez J; Jurado AF; Bonanad S; Pérez-Simón JA; Sanz G;
    Leuk Res; 2015 Jan; 39(1):52-7. PubMed ID: 25487012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone.
    Almeida AM; Pierdomenico F
    Leuk Res; 2012 Sep; 36(9):e211-3. PubMed ID: 22622173
    [No Abstract]   [Full Text] [Related]  

  • 12. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
    Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
    Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of azacitidine and ESA in myelodysplastic patients: the need for prospective studies.
    Breccia M; Loglisci G; Salaroli A; Serrao A; Petrucci L; Zacheo I; Alimena G
    Leuk Res; 2012 Jun; 36(6):682-3. PubMed ID: 22424713
    [No Abstract]   [Full Text] [Related]  

  • 14. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
    Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
    J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azacitidine in patients older than 80 years with acute myeloid leukaemia or myelodysplastic syndromes: a report on 115 patients.
    Peterlin P; Cluzeau T; Jullien M; Ngo Nloga AM; Calleja A; Angeli E; Chevallier P; Guillaume T; Garnier A; Le Bourgeois A; Le Gouill S; Fenaux P; Adès L; Bally C
    Br J Haematol; 2020 Aug; 190(3):461-464. PubMed ID: 32394477
    [No Abstract]   [Full Text] [Related]  

  • 16. Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule.
    Voso MT; Fianchi L; Criscuolo M; Greco M; D'Alo F; Hohaus S; Pagano L; Leone G
    Leuk Res; 2012 Jan; 36(1):e15-7. PubMed ID: 21907408
    [No Abstract]   [Full Text] [Related]  

  • 17. AZA-ESA combo: a new standard for higher risk MDS?
    Mittelman M
    Leuk Res; 2012 Apr; 36(4):389-91. PubMed ID: 22309890
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.
    Prébet T; Gore SD; Thépot S; Esterni B; Quesnel B; Beyne Rauzy O; Dreyfus F; Gardin C; Fenaux P; Vey N
    Br J Haematol; 2012 Jun; 157(6):764-6. PubMed ID: 22390719
    [No Abstract]   [Full Text] [Related]  

  • 19. Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M
    Leuk Res; 2004 May; 28(5):443-6. PubMed ID: 15068895
    [No Abstract]   [Full Text] [Related]  

  • 20. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment.
    Moon JH; Kim SN; Kang BW; Chae YS; Kim JG; Baek JH; Park JH; Song MK; Chung JS; Won JH; Lee SM; Joo YD; Kim YK; Kim HJ; Jo DY; Sohn SK
    Ann Hematol; 2010 Jul; 89(7):681-9. PubMed ID: 20237926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.